Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002919 | 1.00 | CASR (0.44) | CASRADRB2ADRB1ADRB3CA1 | |
| SCHEMBL14537621 | 0.85 | CASR (0.46) | CASRADRB2ADRB1ADRB3CNR1 | |
| SCHEMBL3959541 | 0.85 | CASR (0.46) | CASRADRB2ADRB1ADRB3CNR1 | |
| SCHEMBL5005590 | 0.81 | CASR (0.47) | CASRADRB2ADRB1ADRB3 | |
| SCHEMBL5005587 | 0.81 | CASR (0.47) | CASRADRB2ADRB1ADRB3 | |
| SCHEMBL4232028 | 0.81 | RAB9A (0.51) | CNR1CNR2 | |
| SCHEMBL13868601 | 0.77 | CASR (0.57) | CASR | |
| SCHEMBL13868602 | 0.77 | CASR (0.59) | CASR | |
| SCHEMBL13868603 | 0.77 | CASR (0.62) | CASRADRB1ADRB3 | |
| SCHEMBL3963443 | 0.76 | KDM1A (0.45) | CASRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | claimed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008057282-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | CASR 1/4885ADRB2 199/4885ADRB1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.